XNAS
SHPH
Market cap1mUSD
Jun 03, Last price
0.17USD
1D
-3.06%
1Q
-69.06%
IPO
-99.68%
Name
Shuttle Pharmaceuticals Holdings Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-26.64%
Rev. gr., 5y
%
Revenues
0k
Net income
-9.14b
L+138,610.47%
CFO
-7.33b
L+131,185.38%
Profile
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | 5,011,505 | 4,571 | 2,621 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (5,011,505) | (4,571) | (2,621) | ||||
NOPBT Margin | |||||||
Operating Taxes | 71 | ||||||
Tax Rate | |||||||
NOPAT | (5,011,505) | (4,571) | (2,692) | ||||
Net income | (9,144,797) 138,610.47% | (6,593) 112.71% | (3,099) 157.66% | ||||
Dividends | (402) | ||||||
Dividend yield | 1.98% | ||||||
Proceeds from repurchase of equity | 3,993 | 2,698 | 10,022 | ||||
BB yield | -160.98% | -37.28% | -49.40% | ||||
| Debt | |||||||
Debt current | 1,413,565 | 701 | 748 | ||||
Long-term debt | 238,625 | 796 | 63 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 25,043 | 415 | 865 | ||||
Net debt | (267,954) | (3,967) | (7,606) | ||||
| Cash flow | |||||||
Cash from operating activities | (7,327,230) | (5,581) | (2,710) | ||||
CAPEX | (19) | ||||||
Cash from investing activities | 2,915,765 | (2,830) | |||||
Cash from financing activities | 3,755,193 | 2,570 | 10,623 | ||||
FCF | (5,182,011) | (4,861) | (3,421) | ||||
| Balance | |||||||
Cash | 1,920,144 | 5,464 | 8,417 | ||||
Long term investments | |||||||
Excess cash | 1,920,144 | 5,464 | 8,417 | ||||
Stockholders' equity | (34,578,101) | (25,433) | (8,895) | ||||
Invested Capital | 36,964,187 | 31,044 | 17,321 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 2,887 | 15,907 | 10,351 | ||||
Price | 0.86 88.79% | 0.46 -76.79% | 1.96 | ||||
Market cap | 2,480 -65.73% | 7,238 -64.33% | 20,288 | ||||
EV | (265,474) | 3,271 | 12,682 | ||||
EBITDA | (5,006,042) | (4,564) | (2,554) | ||||
EV/EBITDA | 0.05 | ||||||
Interest | 8,692 | 2,595 | 970 | ||||
Interest/NOPBT | |||||||